Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $7.87M | $62.9M |
| Revenue growth | — | — | — | — | — | 699.0% |
| Gross profit | — | — | — | $0.00 | $795K | — |
| Gross margin | — | — | — | — | 10.1% | — |
| Operating income | -$43.6M | -$93.3M | -$120M | -$99.8M | -$593M | -$213M |
| Operating margin | — | — | — | — | -7527.3% | -338.7% |
| Net income | -$41.7M | -$86.8M | -$104M | -$75.8M | -$568M | -$205M |
| Net margin | — | — | — | — | -7213.8% | -325.3% |
| EPS (diluted) | -$0.43 | -$0.44 | -$0.48 | -$0.35 | -$2.11 | -$0.60 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.5M | -$68.2M | -$96.1M | -$68.0M | -$130M | -$173M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.8M | $132M | $101M | $42.6M | $35.7M | $164M |
| Total assets | $222M | $776M | $672M | $621M | $541M | $595M |
| Total liabilities | $6.71M | $30.2M | $17.1M | $16.4M | $76.8M | $289M |
| Long-term debt | — | — | — | — | — | $47.2M |
| Shareholders' equity | $215M | $746M | $655M | $605M | $464M | $306M |
| Retained earnings | -$76.0M | -$163M | -$267M | -$343M | -$911M | -$1.12B |
| Shares (wtd avg diluted) | 149M | 198K | 217K | 219K | 269K | 342K |
Every figure is extracted from Nuvation Bio Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.